Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sections of 149 breast carcinomas were examined for the over-expression of c-erbB-2 oncoprotein using the avidin-biotin immunoperoxidase technique and two different specific antibodies. These included the polyclonal antibody 21N and the monoclonal antibody 4D5. The tumours were divided into two main groups. The first included 75 cases of invasive ductal and classic invasive lobular carcinomas. The second group consisted of 74 cases with histological types known to have a good prognosis, including mucinous, alveolar variant of invasive lobular, medullary, tubular, cribriform and papillary carcinomas. Fifteen (20%) tumours of the first group were positive with the two antibodies. Fourteen of these were of the ductal type and one was a mixed invasive ductal and lobular carcinoma. Ten of the pure ductal cases had areas of comedo carcinoma. The intraductal elements in a further tumour were positively stained with 21N antibody only. None of the second group of tumours, which included histological types known to have good prognosis, stained with 4D5, although one mucinous carcinoma was positively stained with 21N. These findings suggest that in invasive breast carcinoma immunostaining for c-erbB-2 is mainly seen in a subgroup of ductal tumours, and that almost all other histological types, especially those associated with good prognosis, lack this expression.
 ...
PMID:c-erbB-2 expression in different histological types of invasive breast carcinoma. 167 72

The presence of comedo carcinoma in the intraductal component is an important pathologic feature for predicting local recurrence after breast conserving treatment. Furthermore, the c-erbB-2 gene is frequently overexpressed in comedo carcinoma and it correlates well with gene amplification. This study revealed that 77.0% of the c-erbB-2 amplification positive tumors had intraductal lesions of the comedo type; while only 6.7% of the amplification negative tumors had comedo carcinoma (X(2)=106.6, p<0.0001). Accordingly, when c-erbB-2 amplification is detected in the invasive tumor, intraductal lesions which may co-exist in the tumor are likely to be comedo carcinoma. To predict the presence of comedo type intraductal carcinoma, c-erbB-2 gene amplification was analysed by means of polymerase chain reaction (PCR) from small samples of fine-needle aspiration biopsies. Breast tumors from ten patients were analysed and one had a 3.4-fold amplification of c-erbB-2 gene. The pathological appearance of this case was pure ductal carcinoma in situ with comedo carcinoma. The preoperative detection of c-erbB-2 gene amplification by PCR will be a useful means of selecting patients at high risk for local recurrence after breast conserving treatment.
 ...
PMID:Preoperative detection of C-erbb-2 gene amplification as a predictor of local recurrence after conservative treatment for breast-carcinoma. 2159 76